Thursday, 2 April 2020

Cardiac Monitoring and Cardiac Rhythm Management Device Market Value Share, Supply Demand, Share And Value Chain 2019

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Cardiac Monitoring and Cardiac Rhythm Management Device Market trends over the forecast period.
Cardiac Monitoring and Cardiac Rhythm Management Device Market 2019 Development Status, Sales Revenue, Competitive Landscape, Opportunity Assessment and Potential of the Industry by 2023
Global Cardiac Monitoring and Cardiac Rhythm Management Device Market, by Cardiac Device (Pacemaker and Others), by Cardiac Monitoring (Electrocardiogram), by CRM (Defibrillators and Others), by End-User (Hospitals and Others)–Global Forecast Till 2023
Market Scenario
Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also to growth in the market. The global cardiac monitoring and cardiac rhythm management device market is segmented into types of cardiac devices, types of cardiac monitoring devices, types of cardiac rhythm management devices, and end-users. Further, the types of cardiac devices are segmented into pacemaker, biventricular pacemaker, implantable cardioverter defibrillator, and implantable cardiac loop recorder. Based on the types of cardiac monitoring devices the market is further segmented into electrocardiogram (ECG), Holter monitor, event monitor, implantable loop recorder, and cardiac output monitoring devices. Electrocardiogram (ECG) is further sub-segmented into telelectro-cardiogram, wireless ECG, and lead ECG test. Based on types of cardiac rhythm management devices, the market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. Defibrillations are further sub-segmented into implantable defibrillators and external defibrillators. Based on end-user the market is segmented into hospitals, ambulatory surgical centers, and others.
Global cardiac monitoring and cardiac rhythm management device market size is expected to grow during the forecast period (2018 to 2023) at a CAGR ~4%.
Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market. Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. The increasing demand for minimally invasive surgeries drives the growth of this market. However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market.
However, the high cost of these devices in developing nations, preference of drugs over devices in the cardiac treatment, and limited insurance coverage options are some of the factors which are hampering the growth of the market.
Key Players
Some of the key players in the global cardiac monitoring and cardiac rhythm management device market are Abiomed, Berlin Hearth, Brotionik SE and Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric(GE), Hill Rom Services Inc, Jarvik Hearth. Inc, Koninklijke Philips N.V, LivaNova plc, Medtronic plc, Nihon Kohden Corporation, ReliantHeart Inc, Schiller, and Abbott.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The cardiac monitoring and cardiac rhythm management device market in the Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European cardiac monitoring and cardiac rhythm management device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac monitoring and cardiac rhythm management device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiac monitoring device market in the Middle East and Africa has been segmented into the Middle East and Africa.
The European market is expected to be the second-largest cardiac monitoring device market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of surgeries due to the changing lifestyle is contributing to the growth of the market in this region. Asia-Pacific is expected to be the fastest-growing cardiac monitoring device market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition in the global cardiac monitoring device market by producing cost-effective products that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global cardiac monitoring device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
In terms of market value, North America will dominate the global cardiac monitoring and cardiac rhythm management device market during the forecast period. The increasing investment by North America in cardiac devices over the last few years has led to the growth of the market in this region. Increasing number of cardiac patients, better healthcare infrastructure, and advanced technology in cardiac monitoring equipment have boosted the cardiac monitoring and cardiac rhythm management device market in North America.
Posted by at No comments:

Colposcopy Market To Observe Strong Development By 2019

Market Scenario
A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.

For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.

The Global Colposcopy Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.

Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.

Company Profiles            
  • Carl Zeiss
  • Olympus Corporation
  • Danaher Corporation
  • Philips Healthcare
  • CooperSurgical
  • McKesson Corporation
  • DYSIS Medical
  • Atmos
  • Alliton
  • Seliga Microscopes
  • Karl Kaps
  • Bovie Medical
Segmentation
The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.
On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.
On the basis of instrument portability, the market is classified into portable, fixed, and handheld.
On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.
On the basis of magnification type, the market is classified into fixed magnification and variable magnification
On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.
The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 
The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.
The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.
The Americas is likely to dominate the global colposcopy market owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.
Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  
The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.
Posted by at No comments:

Defibrillators Pads Market Trends, Analysis And Review During 2019 To 2023

Market Synopsis of Global Defibrillators Pads Market:
Key Players
Medtronic, Cardiac Science Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Stryker Corporation, Cardinal Health, Biotronik SE & Co. KG, Defibtech, LLC., and  Mindray Medical are Some of the key players in the Defibrillators pads market.
Market Scenario:
Defibrillation is a procedure that involves the delivery of an electric shock to the heart which causes depolarization of the heart muscles and re-establishes normal conduction of the heart’s electrical impulse. To increase the efficacy of automated defibrillator, pads are attached to them which directly touches victim’s chest and delivers a shock to them. The gel present in the pads acts as a bonding agent and helps the AED pads to adhere firmly to the victim’s skin thus, increasing its efficacy.
Defibrillators Pads Market is expected to register a CAGR of 5% during the forecast period.
The global defibrillators pads market is majorly driven by the increasing number technical advanced devices, increasing number of regulatory approvals, rising geriatric population, abuse of alcohol, the high prevalence of cardiac diseases such as ventricular fibrillation, ventricular tachycardia, and cardiac arrhythmias, and growing penetration of key market players. Furthermore, the increasing awareness of healthcare, favorable reimbursement policies, increasing innovations in research and development of medical devices, as well as rising average income of individuals are fueling the market growth. However, factors such as high cost of defibrillators pads and complicated and costly surgical procedures involved in implantation defibrillators are likely to hamper the growth of the market. Lack of proper healthcare infrastructure, as well as awareness regarding diseases such as cardiac arrhythmia and tachycardia in middle-income countries, are major challenges to the market growth.
Market Segmentation:
The global defibrillators pads market is segmented on the basis of product, age group, distribution channel, and end-user. According to products, the market is segmented into manual external, manual internal, automatic external, and others
Considering the age group, the market is segmented into pediatric defibrillator pads and adult defibrillator pads.
According to the distribution channel, the market is segmented into online pharmacy, retail pharmacy, hospital pharmacy, and others.
On account of end-user, the market is segmented into pre-hospital services, hospitals & clinics, alternate care facilities, public access market, and home healthcare services market.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Analysis:
Americas is the global leader for defibrillators pads market owing to increasing prevalence of cardiovascular diseases among adults and older population and rising more elderly population which increases the vulnerability to hypertension and obesity issues which are indirect causes of heart disease.  Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of defibrillators pads market in the American region. For instance, according to American Heart Association, in 2014, around 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, according to stats presented in reports published by the Centers for Disease Control and Prevention,  heart disease is the most common cause of death and accounted for the death of about 366,000 people in 2015. This growing rate of cardiovascular disorders is expected to have a direct effect on the growth of the defibrillators pads market as it finds whole and sole application in cardiovascular disorders. 
Europe is the second largest market and holds a healthy share in the global defibrillators pads market. The European market is expected to grow at a sturdy growth rate during the forecast period due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure and government initiatives of healthcare reform. For instance, according to 2017 statistics presented by the European Society of Cardiology, there were more than 6 million reported new cases of cardiovascular diseases in the European Union and more than 11 million in Europe as a whole. Additionally, every year 15% of deaths in Europe occur due to cardiovascular diseases. Hence cardiovascular disease being one of the major concern in Europe contributes significantly to the market growth of this region. Additionally, Europe spent around 210 Euros in 2015 for treatment of cardiovascular disorders. This rising healthcare expenditure due to cardiovascular disorders is expected to have a positive impact on the defibrillators pads market. Developed countries such as the U.S. and the U.K. are making it compulsory for certain sports arenas, schools, government facilities, and institutes to store and maintain Automated External Defibrillators (AEDs), as unavailability of defibrillators is the most common cause of sudden cardiac arrest.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Asia Pacific is expected to be the fastest growing market. According to report published by the United Nations in 2015; between 2015 and 2030, the number of older persons aged 60 years or over in the world is predicted to grow by 56 %, out of which 66% of the older population would reside in Asia-Pacific regions. This makes the region prone to metabolic disorders that would further aid the chances of cardiovascular diseases. Owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, favorable insurance and reimbursement policies, and key players such as Boston Scientific Corporation and Medtronic have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia. This is accelerating the growth of the defibrillators pads market. Moreover, raising adaption of western culture has led to increasing sedentary lifestyle due to work culture, addiction to alcohol and smoking, consumption of fast foods which are the indirect causes of cardiovascular diseases and rise in the standard of living in the region also contributes to defibrillators pads market growth. However, on the other hand, factor such as lack of skilled healthcare professionals may slow down the market growth during the forecast period. For instance, according to the Global Burden of Disease Report in 2016, heart diseases is expected to lead to 1.7 million deaths in India. This rising prevalence of heart diseases is expected to propel the growth of the market.
Posted by at No comments:

Coronary Stent Market In Depth Study And Analysis Published, 2019


Coronary stents are small stretchy tube-like devices used to expand the arteries of the patient in order to prevent blockage. A coronary stent is inserted into the artery of a patient suffering from a coronary disease due to the build-up of plaque. It is used for widening the narrowed arteries, and it helps in reducing chest pain and the chance of heart attack

The global coronary stent market is mainly driven by the high prevalence of heart-related diseases and huge demand for diagnosis and treatment methods. Additionally, the increasing availability of diagnostic services for coronary heart diseases also fuels the growth of the market. Moreover, favorable reimbursement policies are likely to boost the market growth.
Many private and government insurance organizations are present in developed countries. Over 50 private insurance companies are present in the U.S. The policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the U.S., if the average cost of three stents is approximately USD 10,000, then USD 7,500 is reimbursed. Additionally, in developed countries such as the U.K., Canada, and Germany, other similar reimbursement policies are available. On the other hand, alternative treatment methods for coronary arteries disease and numerous cases of product recalls may hamper the market growth.
The global coronary stent market is expected to have a CAGR of 7.8% during the forecast period.
Intended Audience
  • Medical Device Manufacturers
  • Medical Device Suppliers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors
Segments  
The global coronary stent market is segmented on the basis of type, mode of delivery, material, and end-user.
On the basis of type, the market is segmented into bare-metal stents, drug-eluting stents, and bio absorbable stents.
On the basis of mode of delivery, the market is segmented into balloon-expandable stents and self-expanding stents.
On the basis of material, the market is segmented into metallic stents, cobalt chromium, platinum chromium, nickel titanium, stainless steel, and others.
On the basis of end-user, the market is segmented into hospitals and clinics, cardiac centers, ambulatory surgical centers, and others.
Regional Analysis of the Global Coronary Stent Market                       
The American coronary stent market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing patient population suffering from coronary heart disease, growing investment in healthcare, and increasing geriatric population. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing coronary stents and the increasing awareness about risk factors for the coronary heart disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for medical devices with progress in coronary stent devices. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of the coronary heart disease.
The European coronary stent market exhibits a positive growth with an increasing emphasis on the diagnosis of heart diseases and other related diseases. Moreover, Germany and the U.K. are the major contributors to the growth of the market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the market.  
Asia Pacific is expected to be the fastest growing market whose growth is attributed to the increasing burden of cardiovascular diseases and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the market.
The Middle Eastern and African market for coronary stents exhibits a steady rise with an increase in the number of healthcare facilities providing treatments for chronic conditions and the flourishing growth of the medical device sector especially diagnostic devices. In the African region, the awareness about the coronary heart disease is increasing the growth of the market.
Key Players in the Global Coronary Stent Market        
Some of the key players in this market are BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), Medtronic plc (Ireland), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), and Translumina GmbH (Germany), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.),STENTYS SA (France), Biosensors International Group, Ltd. (Singapore), Kyoto Medical Planning Co. Ltd. (Japan), Elixir Medical Corporation (U.S.), and Reva Medical Inc. (U.S.), and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cord Blood Banking Services Market To Observe Strong Development By 2019

Market Scenario:
The global cord blood banking services market is expected to exhibit a robust 11.4% CAGR over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global cord blood baking services market is likely to be driven by the growing research into the medical utility of stem cells and cord blood, and the growing establishment of the infrastructure required to create a strong cord blood banking services network.
The umbilical cord blood is a rich source of stem cells and can treat more than 80 genetic diseases. The stem cells also can treat long-lasting diseases such as diabetes, cancer, immune diseases, and blood diseases. Even though a small amount of cord blood can be collected from a single umbilical cord, it comprises a large number of stem cells which can be cultivated and stored for the future use. These cells are collected from hospitals and nursing homes after delivery and stored in cord blood banks (average of 20–25 years) for future use.
Currently, the companies are trying to intensify the awareness about the benefits of cord blood storage. For instance, in 2014, the Institute for Transfusion Medicine and Cord Blood Registry pooled their resources to launch a multi-year initiative for increasing the awareness of cord blood cells.
Factors such as increasing application of cord blood in the treatment of chronic conditions, increasing the focus of federal agencies to set up public banking units, growing awareness regarding this treatment line, and increasing number of facilities across the region are driving the market growth. However, the high cost and probability of non-usage, along with the recommendation driven market by gynecologists are factors hampering the of the Cord Blood Banking Services market growth.
Key Players
Some of the key players in the global cord blood banking services market are China Cord Blood Corporation (China), Cord Blood America, Inc. (U.S.), CBR Systems, Inc. (U.S.), Cordlife Group Limited (Singapore), Cryo-Cell International, Inc. (U.S.), Cryo-Save AG (Netherland), ViaCord, Inc. (U.S.), Virgin Health Bank (Qatar), California Cryobank Stem Cell Services LLC (U.S.), StemCyte, Inc. (India), Norton Healthcare, Inc. (U.S.), Lifeforce Cryobank Sciences Inc. (U.S.), CordVida (Brazil), CryoHoldco de Latinoamerica, S.A.P.I. De C.V. (Mexico), Vita 34 International (Germany), Maze Cord Blood Laboratories (U.S.), The University of Colorado Cord Blood Bank (U.S.), CorCell (U.S.), Lifebank USA (U.S.), Cryoviva Biotech Pvt. Ltd (India), Genecord (U.S.), AlphaCord (U.S.), FamilyCord (U.S.), Cells4Life (UK), Michigan Blood (U.S.), CariCord (U.S.), LifeCell International Pvt. Ltd (India), Stem Cell Cryobank Inc. (U.S.), Viacord Processing Laboratory (VPL) (U.S.), New Jersey Cord Blood Bank (U.S.), Carter BloodCare (U.S.), Americord Registry (U.S.), and others.
Segmentation
The global cord blood banking services market has been segmented on the basis of storage service, component, application, and end-user.
On the basis of storage service, the global cord blood banking services market can be segmented into public cord blood banks, private cord blood banks, and hybrid cord blood banks.
On the basis of application, the global cord blood banking services market can be segmented into cancers, blood disorders, metabolic disorders, immune disorders, and osteoporosis.
On the basis of component, the global cord blood banking services market can be segmented into cord blood, cord tissue, placenta, and others.
On the basis of end-user, the global cord blood banking services market is segmented into hospitals (medical applications), pharmaceutical research (drug discovery), research institutes (scientific research), and others.
Regional Analysis                     
The global cord blood banking services market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global cord blood banking services market owing to the growing number of service providers, increasing awareness about the long-term benefits of cord blood storage, growing investments in public banking, and reduction in the cost involved in storage. Moreover, the U.S. contributes to a significant market share for the global cord blood banking industry. Factors such growing per capita income, increasing number of storage service providers, and high adoption rate for advanced technologies attributed to the largest market share.
The European cord blood banking services market is the second largest market followed by the Asia Pacific region. The Asia Pacific region is expected to dominate the global cord blood banking services market in terms of growth rate during the forecast period. Though the region presently grasps a minimal share in the global market; it is anticipated to exhibit an enormous growth potential owing to the increasing awareness of stem cell banking and vast improvement in health care reforms in countries such as Malaysia, India, Indonesia, and China. Besides, Asia Pacific is a relatively untapped regional market in comparison with developed regions, which is also a reason why it grants better opportunities for the growth of companies.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:
Labels:

Blood Testing Market Volume Forecast And Value Chain Analysis 2019

Global Blood Testing Market Research Report: By Test Type (Complete Blood Count, Blood Chemistry Tests, Enzyme Tests), Disease (Anemia, Infection, Leukemia,), Method (Manual, Automated), End-User (Hospitals, Diagnostic Center) – Global Forecast Till 2023
Market Scenario:
Blood Testing is a laboratory analysis technique that is performed based on the blood sample taken from patient's body through a finger prick or syringes to determine the state of the health. The abnormal functioning of organs can be determined by Blood Testing. These tests are affordable and are commonly performed in hospitals and clinics as a primary checkup for identifying any mild to serious ailments which influence the growth of the Blood Testing market.
The Global market for Blood Testing is expected to grow at a CAGR of approximately 5.5% during 2017 to 2023.
Key Players:
The global blood Testing market is led by some of the fervent players including Baxter International (US), Abbott Laboratories Inc. (US), Gen-Probe, Inc. (US), Becton Dickinson & Company (US), Novartis Diagnostics (US), Biomerica, Inc. (US), Cepheid Corporation (US), Meridian Bioscience, Inc. (US), Trinity Biotech (US), Siemens Healthcare (Germany), Bio-Rad Laboratories Inc. (US), Grifols (Spain), bioMérieux (France), Nanosphere Inc. (US), Roche Diagnostics (Switzerland), Bruker Corporation (US), Alere Inc. (US), Thermo Fisher Scientific Inc. (US) Cardinal Health (US), Beckman Coulter (US), Danaher Corporation (US), and Trividia Health (US)
Industry, Innovation & Related News
September 07, 2018 – Scientists in Australia published their study of a novel blood test they have developed in the JCI Insight Journal. The new blood test that can potentially identify whether a person who had a heart attack in the past is at high risk of having another one. certain lipid biomarkers or fats in the blood to improve upon traditional risk factors in predicting heart disease. The researchers hope to trial it in Australia in the next two to three years.
August 13, 2018 – Engineering for All (Israel), announced the development of a handheld programmable device, named as RevDx (Revolution Diagnostics) that performs automated blood analysis and diagnostics at the point of care. RevDx is meant for anyplace without reliable access to a lab, electricity or Internet connection.
Market Drivers
Growing incidents of chronic diseases and conditions such as cancer, diabetes, heart disease along with the organ failure cases drive the demand for blood testing in multiplications. Needless to say, that the blood testing market is ever increasing. Also, great technological strides being made in electronic monitoring devices and substantial investments transpired into R&D activities are in turn, paying off well, expanding the market size.
Additional factors supporting the market growth include the ever-increasing population that is getting inclined towards the sedentary lifestyle and urbanization. Improving economic conditions are rapidly availing access to the excellent health care, increasing the healthcare expenditures and eventually the market growth.
Conversely, lack of awareness towards the availability and advantages of blood testing is obstructing the market growth.  Also, the unmet clinical needs coupled with the unavailability of external funding; especially in the developing regions are obstructing the market growth. Nevertheless, increasing demand for personal & hand-held diagnostic devices & augmenting demand for the blood testing in the diagnostics that can give fastest & accurate results is fostering the market growth.
Segmentation
The global Blood Testing market has been segmented on the basis of test type, disease, method, and end-user.
On the basis of test type, the global Blood Testing market can be segmented into glucose testing, lipid panel testing, direct LDL testing, Prostate Specific Antigen (PSA) testing, Blood Urea Nitrogen (BUN) testing, A1C testing, high sensitivity C-Reactive Protein (hs-CRP) testing, Vitamin D testing, alt testing, thyroid stimulating hormone testing, creatinine testing, serum nicotine/cotinine testing, AST testing, cortisol testing, testosterone testing, and others.
On the basis of disease, the global Blood Testing market can be segmented into anemia, infection, leukemia, hypokalemia, kidney disorders, heart attack, coronary heart disease, and other diseases.
On the basis of method, the global Blood Testing market can be segmented into manual blood culture testing and automated blood culture testing.
The automated blood culture testing segment is classified into automated blood culture system, blood culture instruments, and others      
On the basis of end-user, the global Blood Testing market is segmented into hospitals, clinics, diagnostic centers, research labs, and others.
Regional Analysis                     
The global Blood Testing market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global Blood Testing market owing to the rising incidence of diseases such as kidney disorders, blood stream infections, other infections, high demand for rapid diagnostic tests, and growing aging population.
The European Blood Testing market is the second largest market owing to the increasing awareness of chronic infection diseases due to the initiatives undertaken by private companies, government organizations, and educational institutions.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to the increasing awareness of the importance of diagnostics in personalized medicines and due to government initiatives, that promote the use of personalized medicines. Furthermore, the increase in a number of government schemes to curb the rising healthcare expenditures in emerging economies is expected to drive the regional market growth.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Competitive Analysis
The blood testing market appears fragmented and fiercely competitive due to many large and small players churning the competition in the market.  Through the strategic partnership, acquisition, expansion, product & technology launch, and collaboration, these players try to gain the competitive edge.
Posted by at No comments:
Labels:

Chordoma Disease Market To Observe Strong Development By 2019

Global Chordoma Disease Market Research Report: By Diagnosis (Biopsy, Imaging, Blood Tests), Treatment (Chemotherapy, Radiation Therapy, Cryosurgery, Surgery, Targeted Therapy), End-User (Hospital, Clinic, Cancer Care Centers) – Global Forecast Till 2023
Market Scenario
Chordoma is a rare, slow-growing type of bone cancer. The increasing awareness programs about cancers led by WHO and UNICEF and the rising healthcare investment in the emerging markets are anticipated to exhibit more opportunities for the growth of the chordoma disease market trends.
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Regionally, the Americas chordoma disease market is segmented into two major regions, namely, North America and South America.
The Americas region holds the largest share of the global chordoma disease market owing to the increasing demand for targeted therapies and growing health concerns. As per an estimate by the American Cancer Society, about 3,300 new cases of bone cancer were diagnosed in 2016 with a death toll of about1490. Thus, the high prevalence of chondroid chordomas is the major hurdle in the market growth.
Key Players
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Regional Analysis                    
The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).
The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.
The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.
Posted by at No comments:
Subscribe to: Posts (Atom)